🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

CDK4/6 Inhibition Beyond Progression in postMONARCH: Are We Seeing the Full Picture? 💥A great editorial offering a critical look at the use of CDK4/6 inhibitors beyond progression, exploring methodological uncertainties and implications for clinical practice.

🔴Online now: HER2DX and survival outcomes in early-stage HER2-positive #breastcancer: an individual patient-level meta-analysis Authors: @prat_aleix, Sara Tolaney, and Guillermo Villacampa thelancet.com/journals/lanon…

New JCO Study: ENGOT-OV60/RAMP 201 💊Avutometinib (MEK1/2 inh) + Defactinib (FAK inh) in recurrent LGSOC 🧬 Dual MAPK + FAK blockade = tumor + stroma suppression 🎯 Efficacy: 🔹ORR 31% overall 🔹44% in KRAS-mut vs 17% WT 🔹PFS: 22.0 mo (KRAS-mut), 12.8 mo (WT) 🔹DOR: 31.1 mo

Don't miss this JCO Oncology Practice review which discusses the need to redefine human epidermal growth factor receptor 2 testing in #BreastCancer in the era of novel #AntibodyDrugConjugates. pubmed.ncbi.nlm.nih.gov/40359470/ Eleonora Nicolò Caterina Gianni Paolo Tarantino #HER2 #HER2low

New in BreastCancerResearch - Multicenter study led by KarenVanBaelen of 2,098 pts w/ early ER+/HER2– lobular BC Over 50% had HER2-low tumors—associated with larger size, multifocality & worse DFS/OS vs HER2-0 Key insights for prognosis & treatment strategies OncoAlert

Dr Hal Burstein (@HaroldBurstein) moderated the Early #BreastCancer Tumor Board at the #HarvardBreastCancerCourse, where breast oncology experts, Dr. E Mittendorf #FainaNakhlis Ada Waks Brittany Bychkovsky, MD, Filipa Lynce, MD, FASCO 🇵🇹 🇺🇸 and #JuliaWong, discussed early breast cancer management through

Dr Sarah Sammons from Dana-Farber’s Breast Oncology Center never fails to spark the most critical questions. How can we best integrate the DB09 results into clinical practice?

Now published! Phase 1/2 palazestrant (OP-1250) monotherapy in ER+ MBC -at RP2D 120 mg/d -mPFS 4.8 mo overall, 5.6 mo in ESR1mut -in “EMERALD eligible” pts (1-2 prior ET for MBC +/- 1L chemo), mPFS > 7 mo regardless of ESR1 status pubmed.ncbi.nlm.nih.gov/40598566/

✍️ Writing is thinking. 👉🏼A powerful editorial in Nature Reviews Bioengineering (Vol. 3, p. 431, 2025) reminds us of something timeless: in science, writing is far more than reporting results. It’s a way of sharpening thought. 👉🏼Even in an age shaped by large-language models,

Here's the most recent #BreastCancer Research Digest-a summary of last week’s publications from select high-impact journals (July 11th-18th, 2025). #ClinicalResearch #CancerTreatment #BCSM #BreastCancerResearch

Out in BreastCancerResearch the results of a phase 1/2 trial testing palazestrant, a new endocrine therapy that retains a unique mechanism of action as CERAN (Complete Estrogen Receptor Antagonist) and SERD The phase 3 trial (OPERA-01) is ongoing OncoAlert …ast-cancer-research.biomedcentral.com/articles/10.11…

New paper 👉The impact of breast radiotherapy on the tumor genome and immune ecosystem 🔓 pubmed.ncbi.nlm.nih.gov/40378044/ @EMittendorf Nicholas Navin Simona F. Shaitelman MD, EdM

🚨Just out in Clinical Cancer Research our analysis on the recurrence timing after neoadjuvant chemo-immunotherapy in early-stage TNBC We analyzed 5 major trials 👉 Early relapse: up to 83% of all recurrences🤯 1/ 🧵 Why this matters 👇 🔗 Full article: doi.org/10.1158/1078-0…

There is an urgent need for a new age algorithm that takes huge existing data sets and calculates 3,5,10 year benefits to Chemotherapy, endocrine therapy, CDK4/6i and bisphosphonates in adjuvant HR+,HER2- Breast Cancer. Predict NHS but new and better. I’m sure AI could help.

Last spring, the ELBCC brought together experts, researchers, and advocates to tackle the toughest clinical challenges in invasive lobular breast cancer After months of collaboration, our work is now out in Annals of Oncology — and I’m excited to share some key takeaways 🧵

Drs. Sarah Sammons (Dr Sarah Sammons) and Kristina Fanucci (Kristina Fanucci) recently updated our consensus based #TreatmentGuideline on the use of #Capivasertib plus #Fulvestrant in patients with advanced estrogen receptor-positive #BreastCancer. 👉physicianresources.dana-farber.org/flexpaper/capi… #MBC

Biomarkers of Response and Resistance to Immune Checkpoint Inhibitors in Breast Cancer thebreastonline.com/article/S0960-…

Out in IJGC the ESGO #INCIP guidelines for the management of patients with gynecological #cancers during #pregnancy Università di Genova OncoAlert Elsevier News Elsevier | Scopus Elsevier | ScienceDirect Elsevier Free link for download: urlsand.esvalabs.com/?u=https%3A%2F…

Circulating tumor DNA mutational landscape and dynamics after progression on a CDK4/6 inhibitor in the PACE phase II trial for metastatic HR-positive/HER2-negative breast cancer☆ -ESMO Open esmoopen.com/article/S2059-…

🧵POSITIVE trial changes how we counsel young HR+ Breast cancer pts ✅74% conceived after pausing endocrine therapy, 65% even with AMH <0.5 ng/mL 🤰Low ovarian reserve ≠ No chance. 📉 LOR was the strongest predictor of reduced fertility 1/3 thebreastonline.com/article/S0960-… OncoAlert